Molecular Cancer Therapeutics高引用文章

• Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes

  引用次数：77

• Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes

  引用次数：33

• Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer

  引用次数：32

• Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer

  引用次数：31

• Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies

  引用次数：27

• Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

  引用次数：26

• Strategies to Address Chimeric Antigen Receptor Tonic Signaling

  引用次数：23

• MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma

  引用次数：22

• Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

  引用次数：21

• We're Not DON Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine

  引用次数：20